Anti-Phosphatidylserine Antibodies in Acute Myocardial Infarction

Abstract

Acute Myocardial Infarction (AMI) is the combined result of environmental factors and personal predispositions. Many factors play a role in AMI including anti-Phospholipid (aPL) antibodies, that may act in the induction of immunological response leading to the development of AMI. Anti-Phosphatidylserine (PS) antibody is detected in various diseases like rheumatoid arthritis, systemic lupus erythematosus and anti-phospholipid antibody syndrome. The study of anti-PS antibody in AMI might shed light on etiologic mechanisms in the pathogenesis of acute coronary syndromes. This study was conducted to evaluate whether prevalence of anti-PS antibodies, in patients who had AMI and to analyze their relationship with traditional cardiovascular risk factors. The prevalence of anti-PS IgG and IgM in a well characterized group of patients with AMI as a case group and in age and sex matched healthy subjects as control group. Sera from two groups were tested to evaluate the presence of IgG and IgM isotypes to anti-PS by ELISA method. The frequencies of positive test for anti-PS IgG were 26.70 and 8.90% among patients and controls respectively with significant difference (p = 0.003). The anti-PS IgM frequencies were 12.20 and 1.10% in patients and the controls, with significant difference (p = 0.005). The findings of this study suggest that anti-PS antibodies seemed to play a role in AMI, independent risk factors for AMI, which may represent a link between autoimmunity and atherosclerosis in patients with AMI. Further studies with bigger sample size including patients with AMI and healthy people are recommended to explore the exact role of anti-PS antibodies in AMI.